S&P 500 7,722.60 ▲ 45.83 (+0.60%) DOW 52,377.57 ▲ 15.97 (+0.03%) NASDAQ 26,477.81 ▲ 308.43 (+1.18%) US Markets Closed â€ĸ 03:37 AM ET

PTGX

Protagonist Therapeutics, Inc.

Price Chart
Latest Quote

$141.12

+0.80 (+0.57%)
Current Price
Previous Close $140.32
Open $140.08
Day High $142.37
Day Low $137.91
Volume 865,918
Fetched: 2026-10-28T02:01:41
Stock Information
Shares Outstanding 64.71M
Total Debt $9.22M
Cash Equivalents $782.58M
Revenue $281.99M
Net Income $82.91M
Sector Healthcare
Industry Biotechnology
Market Cap $9.13B
P/E Ratio 137.01
EPS (TTM) $1.03
Exchange NGM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$8.36B
Sales$281.99M
Income$82.91M
Book/sh$13.01
Cash/sh$12.09
Employees141
Financial Ratios
Quick Ratio21.58
Current Ratio21.71
Debt/Eq1.09
Returns & Margins
ROA4.55%
ROE10.98%
Gross Margin100.00%
Operating Margin74.37%
Profit Margin29.40%
Ownership
Insider Ownership0.71%
Institutional Ownership119.68%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1421.72
P/S32.38
P/B10.85
Analyst Data
Recommendationstrong_buy
Target Price$178.57
Technical Indicators
SMA20$138.94
SMA50$143.56
SMA200$115.70
RSI50.27
ATR5.9517
Shares Float52.89M
Short Float16.78%
Short Ratio13.63
Volatility1.52
Rel Volume1.07
Performance History
Week+2.27%
Month-0.93%
Quarter+6.11%
6 Months+39.43%
YTD+61.87%
Year+88.51%
3 Years+878.64%
5 Years+375.31%
10 Years+617.44%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $141.12 865,900
2026-10-26 $140.32 823,300
2026-10-23 $138.43 409,200
2026-10-22 $139.53 404,400
2026-10-21 $138.08 989,900
2026-10-20 $137.99 774,500
2026-10-19 $134.44 654,200
2026-10-16 $128.75 886,700
2026-10-15 $136.55 707,700
2026-10-14 $136.28 679,000
2026-10-13 $138.49 1,031,800
2026-10-12 $144.88 898,500
2026-10-09 $143.73 762,200
2026-10-08 $139.91 1,000,000
2026-10-07 $140.92 927,300
2026-10-06 $138.69 635,700
2026-10-05 $140.63 1,273,800
2026-10-02 $140.06 760,300
2026-10-01 $139.19 886,200
2026-09-30 $140.89 787,700
2026-09-29 $140.97 508,000
2026-09-28 $142.44 925,500
About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

📰 Latest News
No news articles available at the moment. Check back later for updates on PTGX.
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $46,016,000 $434,433,000 $60,000,000 $26,581,000
Operating Revenue $46,016,000 $434,433,000 $60,000,000 $26,581,000
Expenses
Total Expenses $204,143,000 $181,590,000 $153,652,000 $157,954,000
Other Income Expense $27,000 $250,000 $-201,000 $-80,000
Other Non Operating Income Expenses $27,000 $250,000 $-201,000 $-80,000
Net Non Operating Interest Income Expense $28,789,000 $26,315,000 $14,898,000 $4,060,000
Operating Expense $204,143,000 $181,590,000 $153,652,000 $157,954,000
General And Administrative Expense $44,853,000 $43,462,000 $33,491,000 $31,739,000
Interest Expense - - - $0
Interest Expense Non Operating - - - $0
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Net Interest Income $28,789,000 $26,315,000 $14,898,000 $4,060,000
Interest Income $28,789,000 $26,315,000 $14,898,000 $4,060,000
Normalized Income $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Net Income From Continuing And Discontinued Operation $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Total Operating Income As Reported $-158,127,000 $252,843,000 $-93,652,000 $-131,373,000
Net Income Common Stockholders $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Net Income $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Net Income Including Noncontrolling Interests $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Net Income Continuous Operations $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Pretax Income $-129,311,000 $279,408,000 $-78,955,000 $-127,393,000
Interest Income Non Operating $28,789,000 $26,315,000 $14,898,000 $4,060,000
Operating Income $-158,127,000 $252,843,000 $-93,652,000 $-131,373,000
Special Income Charges - - - $0
Per Share
Diluted EPS $-2.05 $4.23 $-1.39 $-2.60
Basic EPS $-2.05 $4.47 $-1.39 $-2.60
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-156,847,000 $253,669,000 $-92,675,000 $-130,339,000
Reconciled Depreciation $1,280,000 $826,000 $977,000 $1,034,000
EBITDA (Bullshit earnings) $-156,847,000 $253,669,000 $-92,675,000 $-130,339,000
EBIT $-158,127,000 $252,843,000 $-93,652,000 $-131,373,000
Diluted Average Shares $63,573,048 $65,077,722 $56,763,559 $49,042,232
Basic Average Shares $63,573,048 $61,566,989 $56,763,559 $49,042,232
Diluted NI Availto Com Stockholders $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Tax Provision $838,000 $4,220,000 $0 $0
Research And Development $159,290,000 $138,128,000 $120,161,000 $126,215,000
Selling General And Administration $44,853,000 $43,462,000 $33,491,000 $31,739,000
Other Gand A $44,853,000 $43,462,000 $33,491,000 $31,739,000
Total Unusual Items - - - $0
Total Unusual Items Excluding Goodwill - - - $0
Fetched: 2026-10-25
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $614,707,000 $675,295,000 $336,677,000 $215,608,000
Total Assets $668,188,000 $744,725,000 $357,951,000 $247,928,000
Total Non Current Assets $90,614,000 $153,084,000 $2,374,000 $4,851,000
Other Non Current Assets $287,000 $225,000 $225,000 $225,000
Current Assets $577,574,000 $591,641,000 $355,577,000 $243,077,000
Prepaid Assets $5,714,000 $4,238,000 $3,628,000 $5,670,000
Receivables $4,496,000 $168,490,000 $10,332,000 $52,000
Other Receivables $10,000 $248,000 $76,000 $42,000
Accrued Interest Receivable $4,365,000 $3,242,000 $256,000 -
Cash Cash Equivalents And Short Term Investments $567,364,000 $418,913,000 $341,617,000 $237,355,000
Cash And Cash Equivalents $128,390,000 $97,249,000 $186,727,000 $125,744,000
Other Current Assets - - - $42,000
Taxes Receivable - - - $0
Investmentin Financial Assets - - - -
Restricted Cash - - - -
Debt
Total Debt $10,323,000 $10,866,000 $1,141,000 $3,656,000
Long Term Debt And Capital Lease Obligation $8,040,000 $10,356,000 $0 $1,141,000
Current Debt And Capital Lease Obligation $2,283,000 $510,000 $1,141,000 $2,515,000
Liabilities
Total Liabilities Net Minority Interest $53,481,000 $69,430,000 $21,274,000 $32,320,000
Total Non Current Liabilities Net Minority Interest $8,040,000 $22,032,000 $0 $1,141,000
Non Current Deferred Liabilities $0 $11,676,000 $0 -
Current Liabilities $45,441,000 $47,398,000 $21,274,000 $31,179,000
Current Deferred Liabilities $9,550,000 $18,891,000 $3,000 $69,000
Payables And Accrued Expenses $20,844,000 $16,919,000 $13,344,000 $23,628,000
Payables $5,524,000 $4,378,000 $871,000 $4,055,000
Other Payable $185,000 $74,000 $99,000 $415,000
Total Tax Payable $0 $2,689,000 $0 -
Income Tax Payable $0 $2,689,000 $0 -
Accounts Payable $5,339,000 $1,615,000 $772,000 $3,640,000
Equity
Common Stock Equity $614,707,000 $675,295,000 $336,677,000 $215,608,000
Total Equity Gross Minority Interest $614,707,000 $675,295,000 $336,677,000 $215,608,000
Stockholders Equity $614,707,000 $675,295,000 $336,677,000 $215,608,000
Gains Losses Not Affecting Retained Earnings $641,000 $-82,000 $-105,000 $-359,000
Other Equity Adjustments $641,000 $-82,000 $-105,000 $-359,000
Retained Earnings $-470,671,000 $-340,522,000 $-615,710,000 $-536,755,000
Other
Ordinary Shares Number $62,577,897 $61,035,139 $57,708,613 $49,339,252
Share Issued $62,577,897 $61,035,139 $57,708,613 $49,339,252
Tangible Book Value $614,707,000 $675,295,000 $336,677,000 $215,608,000
Invested Capital $614,707,000 $675,295,000 $336,677,000 $215,608,000
Working Capital $532,133,000 $544,243,000 $334,303,000 $211,898,000
Capital Lease Obligations $10,323,000 $10,866,000 $1,141,000 $3,656,000
Total Capitalization $614,707,000 $675,295,000 $336,677,000 $215,608,000
Additional Paid In Capital $1,084,736,000 $1,015,898,000 $952,491,000 $752,722,000
Capital Stock $1,000 $1,000 $1,000 $0
Common Stock $1,000 $1,000 $1,000 $0
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $8,040,000 $10,356,000 $0 $1,141,000
Current Deferred Revenue $9,550,000 $18,891,000 $3,000 $69,000
Current Capital Lease Obligation $2,283,000 $510,000 $1,141,000 $2,515,000
Pensionand Other Post Retirement Benefit Plans Current $12,764,000 $11,078,000 $6,786,000 $4,967,000
Current Accrued Expenses $15,320,000 $12,541,000 $12,473,000 $19,573,000
Investments And Advances $78,638,000 $140,252,000 $0 -
Net PPE $11,689,000 $12,607,000 $2,149,000 $4,626,000
Accumulated Depreciation $-8,315,000 $-7,035,000 $-6,234,000 $-5,254,000
Gross PPE $20,004,000 $19,642,000 $8,383,000 $9,880,000
Leases $2,936,000 $2,424,000 $963,000 $913,000
Other Properties $15,577,000 $15,771,000 $6,277,000 $7,878,000
Machinery Furniture Equipment $1,491,000 $1,447,000 $1,143,000 $1,089,000
Properties $0 $0 $0 $0
Duefrom Related Parties Current $121,000 $165,000,000 $10,000,000 $10,000
Other Short Term Investments $438,974,000 $321,664,000 $154,890,000 $111,611,000
Dueto Related Parties Current - - - $69,000
Fetched: 2026-10-25
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $56,081,000 $182,797,000 $-70,845,000 $-108,932,000
Operating Activities
Operating Cash Flow $57,671,000 $184,152,000 $-70,236,000 $-108,137,000
Cash Flow From Continuing Operating Activities $57,671,000 $184,152,000 $-70,236,000 $-108,137,000
Investing Activities
Capital Expenditure $-1,590,000 $-1,355,000 $-609,000 $-795,000
Investing Cash Flow $-49,332,000 $-299,483,000 $-39,258,000 $91,468,000
Cash Flow From Continuing Investing Activities $-49,332,000 $-299,483,000 $-39,258,000 $91,468,000
Financing Activities
Issuance Of Capital Stock $0 $0 $132,100,000 $14,553,000
Financing Cash Flow $22,864,000 $25,853,000 $170,477,000 $18,838,000
Cash Flow From Continuing Financing Activities $22,864,000 $25,853,000 $170,477,000 $18,838,000
Net Other Financing Charges $-479,000 $-600,000 $-769,000 $-163,000
Net Common Stock Issuance $0 $0 $132,100,000 $14,553,000
Common Stock Issuance $0 $0 $132,100,000 $14,553,000
Other
Interest Paid Supplemental Data $3,694,000 $1,530,000 $0 $0
End Cash Position $128,677,000 $97,474,000 $186,952,000 $125,969,000
Beginning Cash Position $97,474,000 $186,952,000 $125,969,000 $123,890,000
Changes In Cash $31,203,000 $-89,478,000 $60,983,000 $2,169,000
Proceeds From Stock Option Exercised $23,343,000 $26,453,000 $39,146,000 $4,448,000
Net Investment Purchase And Sale $-47,742,000 $-298,128,000 $-38,649,000 $92,263,000
Sale Of Investment $498,843,000 $323,574,000 $152,396,000 $307,137,000
Purchase Of Investment $-546,585,000 $-621,702,000 $-191,045,000 $-214,874,000
Net PPE Purchase And Sale $-1,590,000 $-1,355,000 $-609,000 $-795,000
Purchase Of PPE $-1,590,000 $-1,355,000 $-609,000 $-795,000
Change In Working Capital $146,209,000 $-122,610,000 $-19,511,000 $-7,766,000
Change In Other Working Capital $-21,017,000 $30,567,000 - $-1,601,000
Change In Other Current Liabilities $-903,000 $-2,226,000 $-2,743,000 $-2,661,000
Change In Payables And Accrued Expense $5,610,000 $7,817,000 $-8,531,000 $-11,500,000
Change In Accrued Expense $4,576,000 $4,289,000 $-5,597,000 $-12,715,000
Change In Payable $1,034,000 $3,528,000 $-2,934,000 $1,215,000
Change In Account Payable $3,723,000 $842,000 $-2,868,000 $2,045,000
Change In Tax Payable $-2,689,000 $2,689,000 $0 $0
Change In Income Tax Payable $-2,689,000 $2,689,000 $0 $0
Change In Prepaid Assets $-2,360,000 $-3,768,000 $1,753,000 $3,754,000
Change In Receivables $164,879,000 $-155,000,000 $-9,990,000 $4,242,000
Other Non Cash Items $1,580,000 $2,069,000 $2,529,000 $2,335,000
Stock Based Compensation $45,974,000 $37,554,000 $29,293,000 $24,202,000
Amortization Of Securities $-7,223,000 $-8,875,000 $-4,569,000 $-549,000
Depreciation Amortization Depletion $1,280,000 $826,000 $977,000 $1,034,000
Depreciation And Amortization $1,280,000 $826,000 $977,000 $1,034,000
Depreciation $1,280,000 $826,000 $977,000 $1,034,000
Net Income From Continuing Operations $-130,149,000 $275,188,000 $-78,955,000 $-127,393,000
Effect Of Exchange Rate Changes - $0 $0 $-90,000
Repayment Of Debt - - - $0
Net Issuance Payments Of Debt - - - $0
Net Long Term Debt Issuance - - - $0
Long Term Debt Payments - - - $0
Deferred Tax - - - $0
Deferred Income Tax - - - $0
Issuance Of Debt - - - -
Long Term Debt Issuance - - - -
Gain Loss On Sale Of PPE - - - -
Fetched: 2026-10-25